Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EQ6D
|
|||
| Drug Name |
JCARH125
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1/2 | [1], [2] | |
| Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Clinical trial | [1] | ||
| Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Clinical trial | [1] | ||
| Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Clinical trial | [1] | ||
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Clinical trial | [1] | ||
| Company |
Juno Therapeutics, Inc.
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell maturation protein (TNFRSF17) | Target Info | CAR-T-Cell-Therapy | [1], [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | |||
| REF 2 | ClinicalTrials.gov (NCT03430011) Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.